Literature DB >> 19465452

Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.

A H Ledinek1, S S Jazbec, I Drinovec, U Rot.   

Abstract

A 23-year-old woman with multiple sclerosis developed respiratory symptoms 3 years after introduction of interferon beta-1b. The diagnosis of pulmonary arterial hypertension (PAH) was established. The patient partially responded to sildenafil and bosetan treatment. This is the first report of PAH, associated with interferon beta therapy. As shown in experimental models, interferon treatment can induce PAH by stimulation of thromboxane cascade and secretion of various inflammatory mediators.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19465452     DOI： 10.1177/1352458509104593

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  13 in total

1.  Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.

Authors:  Emma Gibbons; S Promislow; Ross A Davies; George Chandy; Duncan J Stewart; Contreras-Dominguez Vladamir; Carolyn Pugliese; Rosemary Dunne; Lisa M Mielniczuk
Journal:  Can Respir J       Date:  2015-06-17       Impact factor: 2.409

Review 2.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

3.  Astrocyte-derived endothelin-1 inhibits remyelination through notch activation.

Authors:  Timothy R Hammond; Ana Gadea; Jeff Dupree; Christophe Kerninon; Brahim Nait-Oumesmar; Adan Aguirre; Vittorio Gallo
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

4.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

Review 5.  Cardiovascular involvement in patients with different causes of hyperthyroidism.

Authors:  Bernadette Biondi; George J Kahaly
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

6.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

Review 7.  Drug-induced pulmonary arterial hypertension: a review.

Authors:  Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

8.  Evidence for the involvement of type I interferon in pulmonary arterial hypertension.

Authors:  Peter M George; Eduardo Oliver; Peter Dorfmuller; Olivier D Dubois; Daniel M Reed; Nicholas S Kirkby; Nura A Mohamed; Frederic Perros; Fabrice Antigny; Elie Fadel; Benjamin E Schreiber; Alan M Holmes; Mark Southwood; Guy Hagan; Stephen J Wort; Nathan Bartlett; Nicholas W Morrell; John G Coghlan; Marc Humbert; Lan Zhao; Jane A Mitchell
Journal:  Circ Res       Date:  2013-12-13       Impact factor: 17.367

9.  Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.

Authors:  M Nakano; T Fujii; M Hashimoto; N Yukawa; H Yoshifuji; K Ohmura; A Nakaizumi; T Mimori
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

10.  Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.

Authors:  Somayyeh Baghizadeh; Mohammad Ali Sahraian; Mojgan Ghahari
Journal:  Iran J Neurol       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.